TCIM
URGN icon

TIAA CREF Investment Management’s UroGen Pharma URGN Stock Holding History

TIAA CREF Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$358K Buy
9,684
+3,003
+45% +$126K ﹤0.01% 2722
2018
Q4 		$288K Hold
6,681
– – ﹤0.01% 2782
2018
Q3 		$316K Sell
6,681
-4,744
-42% -$220K ﹤0.01% 2879
2018
Q2 		$569K Buy
+11,425
New +$665K ﹤0.01% 2732

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TIAA CREF Investment Management's URGN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its UroGen Pharma (URGN) stake by 45% in Q1 2019, buying an estimated $126K and bringing the position to 9,684 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

TIAA CREF Investment Management first reported a position in URGN in Q2 2018 and has held it in 4 quarters since. The position peaked at $569K in Q2 2018. 74 funds tracked by Wall St. Rank hold URGN as of Q1 2019.

  • TIAA CREF Investment Management held 9,684 shares of UroGen Pharma worth $358K as of Q1 2019.
  • TIAA CREF Investment Management bought 3,003 UroGen Pharma shares in Q1 2019, an estimated $126K.
  • UroGen Pharma made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2722 holding.
  • TIAA CREF Investment Management first reported a position in UroGen Pharma in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's UroGen Pharma position peaked at $569K in Q2 2018.
  • 74 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.